J.P. Morgan analyst Casey Woodring maintained a Buy rating on Icon (ICLR – Research Report) on February 1 and set a price target of $265.00.

Analyst Michael Cherny from Leerink Partners reiterated a Buy rating on Icon (ICLR – Research Report) and decreased the price target to $245.00 from $255.00. Discover outperforming stocks and ...

Baron Funds, an investment management company, released its “Baron Small Cap Fund” fourth-quarter 2024 investor letter. A ...

Consumer Reports tested 58 dog foods from brands including Blue Buffalo, Hill’s Science Diet, and Purina for key nutrients ...

(Reuters) - Matthews International said on Friday it strongly disagreed with proxy advisory firm Institutional Shareholder Services' recommendation that shareholders elect all three of activist ...

That review – to check on the implementation of outstanding recommendations – was drawn up by Dr Seamus O’Reilly in October 2024. The retired consultant found ‘’a number of actions’’ ...

Half a decade on, it seems that little progress has been made on the recommendations suggested for public safety. Ian Paterson treated more than 11,000 patients in the NHS and private hospitals in ...

He said that he instead supports vaccinations and will follow the science in overseeing the $1.7 trillion Department of Health and Human Services, which, among other duties, oversees vaccine research, ...

When you buy through our links, Business Insider may earn an affiliate commission. Learn more As a beauty writer with dry hair, my 5 years of experience have shown me that choosing the best ...

Clinical research conductor ICON Plc downplayed impacts from demand softness from the pharmaceutical and biotechnology industries, surprising investors with a $100 million revenue shortfall that led ...

The draft of the report released Tuesday by the Department of Health and Human Services states that "in the United States, males and females have a 1 in 1000 risk of dying from alcohol use if they ...

ICON's 2025 revenue guidance is $8.05 billion–$8.65 billion, a 1% growth midpoint, versus consensus $8.5 billion. Adjusted EPS for 2025 is forecasted at $13.00–$15.00, flat compared to 2024 ...